The study will enrol some 50 bone marrow or peripheral blood stem cell transplantation leukemia patients who have undergone a round of chemotherapy. The safety and efficacy study will be conducted in five cancer centres across the US.
RGI-2001 is a liposomal formulation of KRN7000, a synthetic derivative of alpha-galactosylceramide. The compound uses REGiMMUNE's reVax technology which promotes transplantation tolerance by inducing regulatory T (Treg) cells.
REGiMMUNE also said it has raised USD5m (EUR3.8m) in the first tranche of a Preferred A financing round by Daiwa Enterprise Co Ltd and Japan Asia Investment Corporation (JAIC).
(USD1 = EUR0.764)
Lupin's Ranluspec (ranibizumab) injection receives US FDA approval
Pharming secures FDA acceptance of Joenja filing for children with APDS
Medtronic seeks expanded US approvals for Hugo robotic surgery system
MiniMed expands Abbott partnership for dual glucose-ketone diabetes sensors
Lupin and Natco secure US FDA approval for generic Eribulin Mesylate Injection
Luminopia agrees international licensing deal for paediatric amblyopia treatment in Japan
FDA accepts Genentech's giredestrant application for early-stage breast cancer
Amgen receives EU marketing authorisation for IMDYLLTRA in ES-SCLC
Hanmi signs licensing deal with Lilly for sonefpeglutide
FDA approves TREMFYA label expansion
GSK reports positive phase III data for bepirovirsen in chronic hepatitis B
Sanofi's venglustat receives FDA priority review for type 3 Gaucher disease
CellCarta partners with Sonic Healthcare to commercialise companion diagnostics through Lab Network